Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2017

View Archived Issues

Preclinical characterization of a novel selective PI3Kalpha inhibitor, GDC-0077

LY-3214996 demonstrates potent antitumor activity in cancer models with MAPK pathway alterations

Discovery and preclinical characterization of novel JAK1 inhibitor AZD-4205

FDA approves Gilead Sciences' Harvoni and Sovaldi in pediatric patients

First data from first-in-human study of FGFR-4 inhibitor FGF-401 reported

Janssen identifies novel FGFR inhibitors

NSTDA patents dihydrofolate reductase inhibitors

Merck KGaA discloses new IRAK-1/4 inhibitors

IASOtoc now available in France, Austria and Germany

Phase II PREVACEbola vaccine study launched in West Africa to evaluate three vaccination strategies

Akorn and Fresenius Kabi in discussions regarding potential acquisition

PeptiDream and Janssen enter discovery and collaboration agreement

Kyowa Hakko Kirin announces positive results from the phase III MAVORIC clinical trial

Themis Bioscience initiates phase I dose-finding study of MV-ZIKA vaccine

Kura Oncology begins phase I study of KO-947 in nonhematological malignancies

Sunshine Lake Pharma, Calitor Sciences patent JAK, FLT-3 and Aurora kinase inhibitors

Medivir announces completion of phase II remetinostat study in CTCL

Assembly Biosciences, IURTC present HBV core protein modulators

Fred Hutch announces faculty and staff achievements

FDA issues complete response letter regarding Merck & Co.'s sitagliption sNDAs

Celgene describes in vivo antitumor activity of anti-CD47 monoclonal antibody CC-90002

Cipla and MEDRx enter into a collaboration for MRX-4TZT

Nanotherapeutics begins enrollment in phase I trial of NTM-1634

Indian FDA approves first autologous dendritic cell-based immuno-oncology product

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...